MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyaf025

Медицинская библиотека · The oncologist · 2025

Response to pembrolizumab in advanced prostate cancer with predictive biomarkers.

Altomare Nicole J, Li Yutai, Neill Clayton, Hussain Maha, VanderWeele David J

СтатьяПеревод в очереди

Аннотация

Checkpoint inhibitors targeting PD-1/PD-L1, such as pembrolizumab, can be effective in a small population of biomarker-selected patients with metastatic prostate cancer (mPC), as has been demonstrated by small case series. The objective of this study is to help identify which biomarker-selected patients are most likely to benefit from pembrolizumab and estimate their likelihood of response. This is a single-center study in which we analyzed clinical data of 18 patients with mPC who were treated with pembrolizumab for a biomarker-driven indication. We found that 38.9% of patients showed a 50% or greater decline in PSA, all of whom had high microsatellite instability (MSI-H). One patient with MSI-H and high tumor mutation burden (TMB-H) had 100% decline in PSA and remained on pembrolizumab after 47 months. Neither MSI-H nor TMB-H, however, was sufficient for response. These results support biomarker testing for all patients with mPC and use of immunotherapy in select populations.

Для цитирования: Altomare Nicole J, Li Yutai, Neill Clayton, Hussain Maha, VanderWeele David J. Response to pembrolizumab in advanced prostate cancer with predictive biomarkers.. The oncologist. 2025. DOI: 10.1093/oncolo/oyaf025.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.